Regulatory Regulatory round-up: A month of key FDA approvals for cancer drugs Pharmaceutical TechnologyFour cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.OncologyRead full story pharminent May 14, 2026 (Last updated: May 14, 2026) Pharmaceutical Technology Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications. Oncology Read full story Post navigation Previous: ECO 2026: gut hormone signals differ in T1D with obesityNext: FDA hands BeOne, Taiho approvals for blood cancers Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026